我們已在上線! 進一步了解
238.97 USD
-3.26
1.35%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
238.97
0.00
0%
1天
-1.35%
5天
3.12%
1個月
4.7%
3個月
17.86%
6個月
6.34%
今年迄今
-2.39%
1年
-11.49%
5年
-7.01%
10年
272.34%
 

關於: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

員工: 11,370

新聞

正面
中性
負面
市場情緒 3個月
正面 22.2%
中性 70.4%
負面 7.4%
正面
Seeking Alpha
5 天前
Top 50 High-Quality Dividend Growth Stocks For October 2026
I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.
Top 50 High-Quality Dividend Growth Stocks For October 2026
中性
GlobeNewsWire
15 天前
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
正面
Seeking Alpha
15 天前
Top 25 High-Growth Dividend Stocks For October 2026
The October 2026 Top 25 High-Growth Dividend Stocks list targets quality companies trading 31% below intrinsic value, with a projected 22.53% annual return. The list's average starting dividend yield is 1.51%, and the companies have grown dividends at 18.81% annually over five years. Stocks are categorized into Deep Value, Growth At A Price, and Balanced Opportunities, supporting diverse investment strategies based on valuation and growth.
Top 25 High-Growth Dividend Stocks For October 2026
中性
MarketBeat
25 天前
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed NYSE: RMD outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care.
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
正面
Barrons
上個月
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Setbacks for competitors have positioned ResMed to capture more market share.
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
中性
Seeking Alpha
上個月
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
負面
Zacks Investment Research
上個月
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
中性
Seeking Alpha
上個月
ResMed: A Significant Upside Despite The Perceived Risk
ResMed has de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. Recurring mask and consumables revenue, now 42% of the sleep and breathing segment, is underappreciated and grew 13% last year. Two major risks—sleep apnea pill and reimbursement—are less material for RMD than feared; Philips' US return poses the most credible threat.
ResMed: A Significant Upside Despite The Perceived Risk
中性
PRNewsWire
上個月
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
中性
GlobeNewsWire
上個月
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. (“ResMed” or the “Company”) (NYSE: RMD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
價格圖表採用Lightweight Charts™實作